INDUCTION CHEMOTHERAPY WITH FOLFOXIRI PLUS CETUXIMAB AND MAINTENANCE WITH CETUXIMAB OR BEVACIZUMAB THERAPY IN UNRESECTABLE KRAS WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTS

Trial Profile

INDUCTION CHEMOTHERAPY WITH FOLFOXIRI PLUS CETUXIMAB AND MAINTENANCE WITH CETUXIMAB OR BEVACIZUMAB THERAPY IN UNRESECTABLE KRAS WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTS

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms MACBETH
  • Most Recent Events

    • 13 Mar 2018 Results of a pooled analysis of five prospective trials ((NCT00719797, NCT02271464, NCT02295930, EudraCT2008-001062-93 and NCT02086656; n=153) assessing prognostic impact of histopathologic parameters, published in the British Journal of Cancer
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 07 Jun 2016 Results (n=784) of pooled analysis of 6 trials (GONO-FOLFOXIRI , FOIB, TRIP, TRIBE, MACBETH and MOMA) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top